Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738147 | 0.84 | PTGS2 (0.80) | PTGS2MAOB | |
| SCHEMBL3738150 | 0.81 | PTGS2 (0.71) | PTGS2MAOB | |
| SCHEMBL7493017 | 0.80 | PTGS2 (0.55) | PTGS2PTGS1ALOX5MAOB | |
| SCHEMBL2329775 | 0.80 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL9720723 | 0.80 | MAOB (0.55) | PTGS2PTGS1MAOB | |
| SCHEMBL9720721 | 0.80 | MAOB (0.55) | PTGS2PTGS1MAOB | |
| SCHEMBL17439304 | 0.78 | PTGS2 (0.64) | PTGS2NFE2L2PTGS1 | |
| SCHEMBL5698418 | 0.78 | PTGS2 (0.64) | PTGS2NFE2L2PTGS1 | |
| SCHEMBL16052791 | 0.78 | PTGS2 (0.64) | PTGS2NFE2L2PTGS1 | |
| SCHEMBL7090629 | 0.77 | PTGS2 (0.55) | PTGS2PTGS1ALOX5MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | PTGS2 122/4885NFE2L2 222/4885PTGS1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.